Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfanilamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.90 |
| ▸ | CA9 | Q16790 | 16/20 | 0.90 |
| ▸ | CA12 | O43570 | 14/20 | 0.90 |
| ▸ | CA1 | P00915 | 14/20 | 0.90 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.90 |
| ▸ | CA7 | P43166 | 7/20 | 0.90 |
| ▸ | CA6 | P23280 | 5/20 | 0.90 |
| ▸ | CA5A | P35218 | 5/20 | 0.90 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.90 |
| ▸ | CA4 | P22748 | 4/20 | 0.90 |
| ▸ | TSHR | P16473 | 3/20 | 0.90 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.90 |
| ▸ | USP2 | O75604 | 1/20 | 0.90 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.90 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfanilamide SCHEMBL11751516 | 0.95 | CA2 (0.90) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL2798899 | 0.95 | CA2 (1.00) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL30659052 | 0.95 | CA2 (1.00) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL740 | 0.95 | CA2 (1.00) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL31544839 | 0.95 | CA2 (1.00) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL5894222 | 0.92 | CA2 (0.94) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL8030126 | 0.92 | CA2 (0.94) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL19210078 | 0.92 | CA2 (0.94) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL22501553 | 0.92 | CA2 (0.94) | CA2CA9CA12CA1CA14 | |
| Sulfanilamide SCHEMBL1155220 | 0.92 | CA2 (0.94) | CA2CA9CA12CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| CN-1831144-A | Granulated sugar and production method thereof | NUERLAN KENJIAHAMAITI (CN) | 2006-09-13 | — | — | CN | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-20160303133-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2983657-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | Numedii, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| CN-105263482-A | Treatment of gastrointestinal and other disorders | NUMEDII INC | 2016-01-20 | — | — | CN | disclosed |
| CN-105218632-A | As peptide or plan peptide, the Preparation Method And The Use of transglutaminase inhibitor | ZEDIRA GMBH | 2016-01-06 | — | — | CN | disclosed |
| WO-2014165823-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | NUMEDII, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| CN-101563359-A | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2009-10-21 | — | — | CN | disclosed |
| CN-1831144-A | Granulated sugar and production method thereof | NUERLAN KENJIAHAMAITI (CN) | 2006-09-13 | — | — | CN | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| US-6326364-B1 | BACTERICIDES | CEDARS-SINAI MEDICAL CENTER | 2001-12-04 | — | — | US | disclosed |
| WO-2000045803-A2 | USE OF 5-AMINOSALICYLATES AS ANTIMICROBIAL AGENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2000-08-10 | — | — | WO | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303133-A1 | TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS | ADRB1, ADRB2, ADRA2B | CA2 3595/4885CA9 3490/4885CA12 3621/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CA2 1000/4885CA9 1018/4885CA12 1252/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CA2 1023/4885CA9 918/4885CA12 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.